741,577 Amneal Pharmaceuticals, Inc. $AMRX Shares Acquired by Congress Asset Management Co.

Key Points

• Congress Asset Management Co. nearly doubled its Amneal Pharmaceuticals stake during the third quarter, acquiring 741,577 additional shares and bringing its holdings to 1.52 million shares worth approximately $30.7 million.
• Amneal reported quarterly EPS of $0.30, beating estimates by $0.06, on revenue of $796.2 million. The company guided for fiscal 2026 EPS of $0.96–$1.06.
• Analyst sentiment remains favorable, with nine Buy ratings and one Hold rating; the consensus price target is $21, while recent targets range from $20 to $27. However, company insiders sold 413,016 shares worth about $7.2 million over the past three months.

Congress Asset Management Co. raised its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 94.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,524,355 shares of the company's stock after buying an additional 741,577 shares during the quarter. Congress Asset Management Co. owned 0.48% of Amneal Pharmaceuticals worth $30,701,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of AMRX. Public Employees Retirement System of Ohio bought a new stake in Amneal Pharmaceuticals in the second quarter valued at $29,000. KBC Group NV acquired a new position in Amneal Pharmaceuticals during the 1st quarter worth approximately $80,000. Integrated Wealth Concepts LLC bought a new position in Amneal Pharmaceuticals in the second quarter worth approximately $139,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Amneal Pharmaceuticals in the second quarter worth approximately $180,000. Finally, Strs Ohio grew its stake in Amneal Pharmaceuticals by 158.5% in the first quarter. Strs Ohio now owns 10,600 shares of the company's stock valued at $132,000 after acquiring an additional 6,500 shares during the period. 31.82% of the stock is currently owned by institutional investors.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Nikita Shah sold 146,403 shares of the business's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the transaction, the executive vice president owned 253,390 shares of the company's stock, valued at approximately $4,436,858.90. The trade was a 36.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jason Daly sold 210,000 shares of the company's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the transaction, the executive vice president owned 35,171 shares of the company's stock, valued at $611,975.40. This trade represents a 85.65% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is owned by insiders.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $20.30 on Wednesday. The company has a fifty day moving average price of $18.39 and a 200-day moving average price of $15.79. The firm has a market cap of $6.48 billion, a price-to-earnings ratio of 41.43, a PEG ratio of 2.39 and a beta of 1.22. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. Amneal Pharmaceuticals, Inc. has a 1 year low of $9.56 and a 1 year high of $21.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.06. The business had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.95 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. The Goldman Sachs Group reaffirmed a "buy" rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Leerink Partners started coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 9th. They set an "outperform" rating and a $23.00 price target for the company. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an "overweight" rating in a report on Thursday, September 17th. Oppenheimer started coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an "outperform" rating and a $27.00 price objective on the stock. Finally, UBS Group reiterated a "buy" rating on shares of Amneal Pharmaceuticals in a report on Thursday, October 1st. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $21.00.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a global pharmaceutical company that develops, manufactures and markets a broad portfolio of generic and specialty medicines. The company focuses on complex and difficult-to-manufacture products, including injectables, biosimilars, ophthalmic medicines, respiratory treatments, oncology products, transdermal formulations and other dosage forms.

Amneal also operates a specialty pharmaceutical business focused on branded products in areas such as central nervous system disorders, endocrinology and other therapeutic categories.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.